Tools   Select Another Resource Report Type

http://www.predect.eu/

Project that aims to create more appropriate in vitro platforms for target validation and drug discovery for breast, prostate and lung cancers. Laboratory platforms to validate whether target modulation would provide a clinical benefit are usually highly reductionist, often using long-established cell lines growing in 2 dimensions in vitro. These models do not reflect the complexity and heterogeneity of a tumor in situ, where biochemical pathways are wired with connections to the complex tumor environment provided by the stroma. PREDECT has the goal of comparing the pathological and molecular profiles of novel in vitro platforms with those of human tumors. Because obtention of clinical material presents both logistics and quality problems for ongoing and intense studies of target validation, PREDECT aims to use material from genetically engineered mouse models, and some advanced xenografts, whose pathology and molecular profiles closely match cohorts of human tumors. PREDECT hopes to provide more appropriate in vitro platforms both for target validation and subsequent preclinical studies which will replace a current cascade of tests which are poorly predictive of clinical activity. The project is expected to shift paradigms in cell biology as well as in preclinical target validation where it should permit greater predictivity of drug efficacy in patient cohorts.

Proper citation: PREDECT (RRID:SCR_003883) Copy   

•   Source: SciCrunch Registry

http://www.alzheimer-europe.org/Research/PharmaCog

Project aiming to tackle bottlenecks in Alzheimer''''s disease research and drug discovery by developing and validating new tools to test candidate drugs for the treatment of symptoms and disease in a faster and more sensitive way. They will provide the tools needed to define more precisely the potential of a drug candidate, reduce the development time of new medicines and thus accelerate the approvals of promising new medicines. By bringing together databases of previously conducted clinical trials and combining the results from blood tests, brain scans and behavioral tests, the scientists will develop a ''''signature'''' that gives more accurate information on the progression of the disease and the effect of candidate drugs than current methods do. The scientists will conduct parallel studies in laboratory models, healthy volunteers and patients in order to better predict good new drugs as early as possible. This will enable them, for instance, to find out how memory loss in Alzheimer''''s disease can be simulated in healthy volunteers, for example with sleep deprivation or drugs that temporarily affect the memory, in order to test the effect of candidate-medicines early in the drug development process.

Proper citation: PharmaCog (RRID:SCR_003878) Copy   

•   Source: SciCrunch Registry

https://sites.google.com/site/p2tconsortium/

A three-member pharmaceutical industry consortium that aims to provide a new platform to improve access to information about clinical trials for patients and providers. The platform aims to enhance the existing clinicaltrials.gov by providing more detailed and patient-friendly information about available trials and embedding a machine-readable target health profile to improve the ability of healthcare software to match individual health profiles with applicable clinical trials. Using clinicaltrials.gov as its foundation and Eli Lilly''''s Application Programming Interface (API), the consortium is focused on creating an open platform to make this data more amenable to patients and providers, as well as creating an opportunity to integrate a patient''''s electronic health record into the clinical trial matching service. This feature will allow patients to search for trials using their own Blue Button data. The following features are planned add-ons to clinicaltrials.gov: * Target Profile is a machine readable query, that can be executed against an electronic file (or record) with patient health data such as an Electronic Health Record (EHR), an Electronic Medical Record (EMR) or Personally Controlled Health Record (PCHR) * Augmented Content is public, IRB approved information about the study that has not been published on clinicaltrials.gov, and that is shared with / targeted for patients with a matching Target Profile. The following are the incremental goals of the consortium: * Advancement of the Lilly API platform to support read/write interaction and additional data objects and information. * The initial 3 sponsor organizations - Lilly, Pfizer and Novartis - will upload Target Profiles for a select set of clinical trials. A Target Profile is a machine interpretable description of the characteristics of patients who may qualify for that trial i.e. a query that can be executed against a patient''''s electronic health record or personal health record. Additionally, sponsors of clinical research studies will also be able to upload Augmented Content to the Lilly Platform to supplement information on clinicaltrials.gov with additional, patient-focused information about the study, e.g., a study brochure and practical information on how to contact investigational sites. * A matching service, developed by Corengi, will compare Target Profiles to a de-dentified personally controlled health record (PCHR), represented by patient''''s Blue Button Plus CCDA XML document. * Integration into a patient community platform from Avado for providing the patient PCHR and presenting the results of the match service. The patient will be able to explore the respective matching studies for additional information and next steps such as contacting a nearby investigator clinic or hospital. The first demo of the prototype was made available on June 2014, built on a database of anonymized patient health records from different clinical research studies sponsored by Lilly, Novartis, and Pfizer. Other website: http://portal.lillycoi.com/

Proper citation: Patients to Trials Consortium (RRID:SCR_003877) Copy   

•   Source: SciCrunch Registry

http://www.chevron.com/

An American multinational energy corporation headquartered in San Ramon, California, and active in more than 180 countries, that is engaged in every aspect of the oil, gas, and geothermal energy industries, including exploration and production; refining, marketing and transport; chemicals manufacturing and sales; and power generation. Chevron is one of the world's largest oil companies; as of 2013, it ranked third in the Fortune Global 500-2014 list of the world's largest companies. (Adapted from Wikipedia)

Proper citation: Chevron Corporation (RRID:SCR_003794) Copy   

•   Source: SciCrunch Registry

http://www.criver.com/

Commercial organism provider selling mice, rats and other model animals. American corporation specializing in a variety of pre-clinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries. It also supplies assorted biomedical products and research and development outsourcing services for use in the pharmaceutical industry. (Wikipedia)

Proper citation: Charles River Laboratories (RRID:SCR_003792) Copy   

•   Source: SciCrunch Registry

http://www.bioreliance.com/

Company that provides testing and manufacturing services to pharmaceutical and biopharmaceutical companies that span the product cycle from early pre-clinical development to licensed production.

Proper citation: BioReliance (RRID:SCR_003791) Copy   

•   Source: SciCrunch Registry

http://purl.bioontology.org/ontology/MSTDE-FRE

Metathesaurus Version of Minimal Standard Terminology Digestive Endoscopy, French Translation, 2001

Proper citation: Minimal Standard Terminology of Digestive Endoscopy - French (RRID:SCR_003830) Copy   

•   Source: SciCrunch Registry

http://www.antilope-project.eu/

Consortium focused on making electronic health data more interoperable, both within and outside of Europe, with the intention to create, validate, and disseminate standard methods to test and certify electronic health solutions and services. In particular it will: Drive the adoption of recognized sets of profiles and underlying standards for eHealth interoperability, and improve the impact of the EU and International eHealth standards development process; Define and validate testing guidelines and common approaches on Interoperability Labelling and Certification processes at European and at National / Regional level. Four work packages were created to provide guidelines, recommendations and frameworks based on a set of use cases, related profiles and standards, Interoperability Quality Management System, testing guidelines and Certification process. All the deliverables will be presented for validation and promotion by organizing workshops across Europe.

Proper citation: Antilope Project (RRID:SCR_003829) Copy   

•   Source: SciCrunch Registry

http://www.selleckchem.com/

An Antibody supplier

Proper citation: Selleck Chemicals LLC (RRID:SCR_003823) Copy   

•   Source: SciCrunch Registry

http://www.bioclinica.com/

Pennsylvania-based company supporting pharmaceutical and medical device innovation with imaging core lab, EDC, IVR / IWR, CTMS, and supply chain forecasting and optimization. Its initial service was medical imaging for clinical trials. It is used to capture, collect, control quality, provide blinded reading services to the final delivery to the sponsor company and to the FDA or EMEA if required for medical images in a wide range of imaging modalities. (Wikipedia)

Proper citation: BioClinica (RRID:SCR_003789) Copy   

•   Source: SciCrunch Registry

http://www.musc.edu/

Public medical school in Charleston, South Carolina. Opened in 1824 as small private college aimed at training physicians. One of the oldest continually operating schools of medicine in the United States and the oldest in the Deep South.

Proper citation: Medical University of South Carolina; South Carolina; USA (RRID:SCR_003828) Copy   

•   Source: SciCrunch Registry

http://www.europeanlung.org/en/projects-and-research/projects/airprom/

Consortium focused on developing computer and physical models of the airway system for patients with asthma and chronic obstructive pulmonary disease (COPD). Developing accurate models will better predict how asthma and COPD develop, since current methods can only assess the severity of disease. They aim to bridge the gaps in clinical management of airways-based disease by providing reliable models that predict disease progression and the response to treatment for each person with asthma or COPD. A data management platform provides a secure and sustainable infrastructure that semantically integrates the clinical, physiological, genetic, and experimental data produced with existing biomedical knowledge from allied consortia and public databases. This resource will be available for analysis and modeling, and will facilitate sharing, collaboration and publication within AirPROM and with the broader community. Currently the AirPROM knowledge portal is only accessible by AirPROM partners.

Proper citation: AirPROM (RRID:SCR_003827) Copy   

•   Source: SciCrunch Registry

http://www.quretec.com/

Commercial organization that builds software for collection, management, and analysis of complex data, most typical in biomedical domain. The solutions are generic and can be used for multitude of uses and application domains.

Proper citation: Quretec (RRID:SCR_003826) Copy   

•   Source: SciCrunch Registry

http://www.agedbrainsysbio.eu/

Consortium focused on identifying the foundational pathways responsible for the aging of the brain, with a focus on Late Onset Alzheimer's disease. They aim to identify the interactions through which the aging phenotype develops in normal and in disease conditions; modeling novel pathways and their evolutionary properties to design experiments that identify druggable targets. As early steps of neurodegenerative disorders are expected to impact synapse function the project will focus in particular on pre- or postsynaptic protein networks. The concept is to identify subsets of pathways with two unique druggable hallmarks, the validation of interactions occurring locally in subregions of neurons and a human and/or primate accelerated evolutionary signature. The consortium will do this through six approaches: * identification of interacting protein networks from recent Late-Onset Alzheimer Disease-Genome Wide Association Studies (LOAD-GWAS) data, * experimental validation of interconnected networks working in subregion of a neuron (such as dendrites and dendritic spines), * inclusion of these experimentally validated networks in larger networks obtained from available databases to extend possible protein interactions, * identification of human and/or primate positive selection either in coding or in regulatory gene sequences, * manipulation of these human and/or primate accelerated evolutionary interacting proteins in human neurons derived from induced Pluripotent Stem Cells (iPSCs) * modeling predictions in drosophila and novel mouse transgenic models * validation of new druggable targets and markers as a proof-of-concept towards the prevention and cure of aging cognitive defects. The scientists will share results and know-how on Late-Onset Alzheimer Disease-Genome Wide Association Studies (LOAD-GWAS) gene discovery, comparative functional genomics in mouse and drosophila models, in mouse transgenic approaches, research on human induced pluripotent stem cells (hiPSC) and their differentiation in vitro and modeling pathways with emphasis on comparative and evolutionary aspects. The four European small to medium size enterprises (SMEs) involved will bring their complementary expertise and will ensure translation of project results to clinical application.

Proper citation: AgedBrainSYSBIO (RRID:SCR_003825) Copy   

•   Source: SciCrunch Registry

http://harvard.eagle-i.net/i/0000012e-58c7-d44f-55da-381e80000000

Core to provide gene expression data analysis service. Activities range from the provision of services to fully collaborative grant funded investigations.

Proper citation: Harvard Partners HealthCare Center for Personalized Genetic Medicine Bioinformatics Core Facility (RRID:SCR_000882) Copy   

•   Source: SciCrunch Registry

https://projects.propublica.org/nonprofits/organizations/364298517

Non-profit charitable organization that benefits philanthropy, voluntarism and grantmaking foundations, focusing specifically on private independent foundations programs. (http://non-profit-organizations.findthebest.com/l/558154/Makray-Family-Foundation)

Proper citation: Makray Family Foundation (RRID:SCR_000916) Copy   

•   Source: SciCrunch Registry

http://www.frontiersci.com/

A commercial vendor of chemicals that provides custom synthesis of a wide variety of organic compounds. Frontier Scientific has capabilities for custom work in organoborons, organotins, porphyrins, silanes, halogenations, catalysts and cross couplings using Suzuki, Stille, and Kumada processes.

Proper citation: Frontier Scientific Chemical Supplier (RRID:SCR_000914) Copy   

•   Source: SciCrunch Registry

http://www.dundee.ac.uk/

University in Scotland, UK that provides undergraduate and doctoral degree programs.

Proper citation: University of Dundee; Scotland; United Kingdom (RRID:SCR_000997) Copy   

•   Source: SciCrunch Registry

http://www.tufts.edu/

Private research university in Medford and Somerville, Massachusetts, United States, with additional facilities in Boston and Grafton, as well as Talloires, France. Provides undergraduate, graduate, and professional degree programs.

Proper citation: Tufts University; Massachusetts; USA (RRID:SCR_000994) Copy   

•   Source: SciCrunch Registry

http://purl.bioontology.org/ontology/PHYLONT

Ontology for Phylogenetic Analysis

Proper citation: Phylogenetic Ontology (RRID:SCR_000912) Copy   

•   Source: SciCrunch Registry